TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
This Quarter Return
+11.93%
1 Year Return
+18.15%
3 Year Return
+62.34%
5 Year Return
+140.22%
10 Year Return
+499.57%
AUM
$2.58B
AUM Growth
+$2.58B
(+9.9%)
Cap. Flow
+$15.1M
Cap. Flow
% of AUM
0.59%
Top 10 Holdings %
Top 10 Hldgs %
43.75%
Holding
150
New
7
Increased
20
Reduced
25
Closed
10
Top Buys
| 1 |
Amgen
AMGN
|
$59.6M |
| 2 |
Johnson & Johnson
JNJ
|
$33.8M |
| 3 |
Viatris
VTRS
|
$16.2M |
| 4 |
McKesson
MCK
|
$14.5M |
| 5 |
Thermo Fisher Scientific
TMO
|
$13.3M |
Top Sells
| 1 |
AGN
Allergan plc
AGN
|
$29.5M |
| 2 |
MDCO
Medicines Co
MDCO
|
$26.2M |
| 3 |
Incyte
INCY
|
$25M |
| 4 |
Abbott
ABT
|
$19.1M |
| 5 |
Centene
CNC
|
$18.2M |
Sector Composition
| 1 | Healthcare | 91.08% |
| 2 | Real Estate | 3.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
DOC
51
DELISTED
PHYSICIANS REALTY TRUST
DOC
| $10.5M | 0.41% |
530,672
| – | – |
|
52
Health Care Select Sector SPDR Fund
XLV
$33.9B
| $10.5M | 0.41% |
+140,600
| New | +$10.5M |
|
|
53
Centene
CNC
$14.5B
| $10.3M | 0.4% |
144,300
-255,700
| -64% | -$18.2M |
|
|
PVLA
54
Palvella Therapeutics, Inc. Common Stock
PVLA
$583M
| $10.2M | 0.4% |
3,940,084
-205,874
| -5% | -$535K |
|
|
ENDP
55
DELISTED
Endo International plc
ENDP
| $10.2M | 0.4% |
914,548
| – | – |
|
56
Bristol-Myers Squibb
BMY
$96.5B
| $10.1M | 0.39% |
+186,500
| New | +$10.1M |
|
57
Acadia Healthcare
ACHC
$2.17B
| $10.1M | 0.39% |
231,200
+166,300
| +256% | +$7.25M |
|
58
Galapagos
GLPG
$2.05B
| $9.98M | 0.39% |
115,738
| – | – |
|
59
Puma Biotechnology
PBYI
$257M
| $9.68M | 0.38% |
260,200
| – | – |
|
|
CCP
60
DELISTED
Care Capital Properties, Inc.
CCP
| $9.27M | 0.36% |
345,022
| – | – |
|
|
TTPH
61
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
| $9.23M | 0.36% |
1,004,322
+812,000
| +422% | +$7.46M |
|
62
CytomX Therapeutics
CTMX
$343M
| $9.16M | 0.36% |
530,092
-225,998
| -30% | -$3.9M |
|
63
Ardelyx
ARDX
$1.54B
| $8.09M | 0.31% |
639,370
| – | – |
|
|
ADAP
64
Adaptimmune Therapeutics
ADAP
$15.3M
| $8.08M | 0.31% |
1,466,368
+900,000
| +159% | +$4.96M |
|
|
AKRX
65
DELISTED
Akorn, Inc.
AKRX
| $7.89M | 0.31% |
327,735
| – | – |
|
66
Natera
NTRA
$23.2B
| $7.83M | 0.3% |
882,358
| – | – |
|
67
Karyopharm Therapeutics
KPTI
$58.8M
| $7.77M | 0.3% |
605,224
+104,900
| +21% | +$1.35M |
|
|
CLLS
68
Cellectis
CLLS
$260M
| $7.45M | 0.29% |
310,250
| – | – |
|
|
MNTA
69
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $6.73M | 0.26% |
504,400
+197,800
| +65% | +$2.64M |
|
|
PRAH
70
DELISTED
PRA Health Sciences, Inc.
PRAH
| $6.65M | 0.26% |
102,000
| – | – |
|
|
LTC
71
LTC Properties
LTC
$1.67B
| $6.53M | 0.25% |
136,212
| – | – |
|
|
SAGE
72
DELISTED
Sage Therapeutics
SAGE
| $6.43M | 0.25% |
90,480
+36,480
| +68% | +$2.59M |
|
|
GBT
73
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $6.36M | 0.25% |
172,500
-208,800
| -55% | -$7.69M |
|
74
Cardinal Health
CAH
$35.7B
| $6.25M | 0.24% |
76,600
-75,900
| -50% | -$6.19M |
|
|
EPZM
75
DELISTED
Epizyme, Inc
EPZM
| $6.21M | 0.24% |
362,000
-38,000
| -10% | -$652K |
|